Search for "key intermediate" in Full Text gives 260 result(s) in Beilstein Journal of Organic Chemistry. Showing first 200.
Beilstein J. Org. Chem. 2020, 16, 989–1000, doi:10.3762/bjoc.16.88
Graphical Abstract
Scheme 1: Synthesis of acridan-based compounds 3–6. Reagents and conditions: (a) bromoethane, KOH, tetrabutyl...
Figure 1: Theoretically calculated HOMO and LUMO levels distributions and optimized geometries of 3–6 DFT cal...
Figure 2: DSC curves of compounds 4 and 5.
Figure 3: Absorption and PL spectra (λex = 330 nm) of compounds 3–6. a) Absorption spectra as neat films, dil...
Figure 4: a) Cyclic voltammogram of derivative 3 in dichloromethane (a three-electrode cell consisting of a p...
Figure 5: TOF photocurrent transients for holes in vacuum-deposited layers of compound 4 (a); hole mobility v...
Figure 6: Energy diagrams of the fabricated OLEDs (a); normalized electroluminescence spectra of devices A–C ...
Beilstein J. Org. Chem. 2020, 16, 818–832, doi:10.3762/bjoc.16.75
Graphical Abstract
Figure 1: Examples for catalytically or biologically active molecules containing five-membered P-heterocyclic...
Scheme 1: Comparison of the isomerization of 1-phenyl-3-phospholene oxide (5), 1-phenyl-3-methyl-3-phospholen...
Scheme 2: Three possible reaction mechanisms considered in the theoretical studies for the isomerization of 3...
Figure 2: The full time experimental kinetic curves (a); The initial part of the kinetic curves of 1c–f and 1h...
Scheme 3: Computed reaction mechanism of the 3-phospholene oxide (1) 2-phospholene oxide (4) isomerization un...
Scheme 4: Computed reaction mechanism of the 3-phospholene oxide (1) 2-phospholene oxide (4) isomerization un...
Beilstein J. Org. Chem. 2020, 16, 738–755, doi:10.3762/bjoc.16.68
Graphical Abstract
Scheme 1: Intramolecular (A) and intermolecular (B) enyne metathesis reactions.
Scheme 2: Ene–yne and yne–ene mechanisms for intramolecular enyne metathesis reactions.
Scheme 3: Metallacarbene mechanism in intermolecular enyne metathesis.
Scheme 4: The Oguri strategy for accessing artemisinin analogs 1a–c through enyne metathesis.
Scheme 5: Access to the tetracyclic core of nanolobatolide (2) via tandem enyne metathesis followed by an Eu(...
Scheme 6: Synthesis of (−)-amphidinolide E (3) using an intermolecular enyne metathesis as the key step.
Scheme 7: Synthesis of amphidinolide K (4) by an enyne metathesis route.
Scheme 8: Trost synthesis of des-epoxy-amphidinolide N (5) [72].
Scheme 9: Enyne metathesis between the propargylic derivative and the allylic alcohol in the synthesis of the...
Scheme 10: Synthetic route to amphidinolide N (6a).
Scheme 11: Synthesis of the stereoisomeric precursors of amphidinolide V (7a and 7b) through alkyne ring-closi...
Scheme 12: Synthesis of the anthramycin precursor 8 from ʟ-methionine by a tandem enyne metathesis–cross metat...
Scheme 13: Synthesis of (−)‐clavukerin A (9) and (−)‐isoclavukerin A (10) by an enyne metathesis route startin...
Scheme 14: Synthesis of (−)-isoguaiene (11) through an enyne metathesis as the key step.
Scheme 15: Synthesis of erogorgiaene (12) by a tandem enyne metathesis/cross metathesis sequence using the sec...
Scheme 16: Synthesis of (−)-galanthamine (13) from isovanilin by an enyne metathesis.
Scheme 17: Application of enyne metathesis for the synthesis of kempene diterpenes 14a–c.
Scheme 18: Synthesis of the alkaloid (+)-lycoflexine (15) through enyne metathesis.
Scheme 19: Synthesis of the AB subunits of manzamine A (16a) and E (16b) by enyne metathesis.
Scheme 20: Jung's synthesis of rhodexin A (17) by enyne metathesis/cross metathesis reactions.
Scheme 21: Total synthesis of (−)-flueggine A (18) and (+)-virosaine B (19) from Weinreb amide by enyne metath...
Scheme 22: Access to virgidivarine (20) and virgiboidine (21) by an enyne metathesis route.
Scheme 23: Enyne metathesis approach to (−)-zenkequinone B (22).
Scheme 24: Access to C-aryl glycoside 23 by an intermolecular enyne metathesis/Diels–Alder cycloaddition.
Scheme 25: Synthesis of spiro-C-aryl glycoside 24 by a tandem intramolecular enyne metathesis/Diels–Alder reac...
Scheme 26: Pathways to (−)-exiguolide (25) by Trost’s Ru-catalyzed enyne cross-coupling and cross-metathesis [94].
Beilstein J. Org. Chem. 2020, 16, 691–737, doi:10.3762/bjoc.16.67
Graphical Abstract
Scheme 1: Pharmaceuticals possessing a silicon or boron atom.
Scheme 2: The first Cu-catalyzed C(sp3)–Si bond formation.
Scheme 3: Conversion of benzylic phosphate 6 to the corresponding silane.
Scheme 4: Conversion of alkyl triflates to alkylsilanes.
Scheme 5: Conversion of secondary alkyl triflates to alkylsilanes.
Scheme 6: Conversion of alkyl iodides to alkylsilanes.
Scheme 7: Trapping of intermediate radical through cascade reaction.
Scheme 8: Radical pathway for conversion of alkyl iodides to alkylsilanes.
Scheme 9: Conversion of alkyl ester of N-hydroxyphthalimide to alkylsilanes.
Scheme 10: Conversion of gem-dibromides to bis-silylalkanes.
Scheme 11: Conversion of imines to α-silylated amines (A) and the reaction pathway (B).
Scheme 12: Conversion of N-tosylimines to α-silylated amines.
Scheme 13: Screening of diamine ligands.
Scheme 14: Conversion of N-tert-butylsulfonylimines to α-silylated amines.
Scheme 15: Conversion of aldimines to nonracemic α-silylated amines.
Scheme 16: Conversion of N-tosylimines to α-silylated amines.
Scheme 17: Reaction pathway [A] and conversion of aldehydes to α-silylated alcohols [B].
Scheme 18: Conversion of aldehydes to benzhydryl silyl ethers.
Scheme 19: Conversion of ketones to 1,2-diols (A) and conversion of imines to 1,2-amino alcohols (B).
Scheme 20: Ligand screening (A) and conversion of aldehydes to α-silylated alcohols (B).
Scheme 21: Conversion of aldehydes to α-silylated alcohols.
Scheme 22: 1,4-Additions to α,β-unsaturated ketones.
Scheme 23: 1,4-Additions to unsaturated ketones to give β-silylated derivatives.
Scheme 24: Additions onto α,β-unsaturated lactones to give β-silylated lactones.
Scheme 25: Conversion of α,β-unsaturated to β-silylated lactams.
Scheme 26: Conversion of N-arylacrylamides to silylated oxindoles.
Scheme 27: Conversion of α,β-unsaturated carbonyl compounds to silylated tert-butylperoxides.
Scheme 28: Catalytic cycle for Cu(I) catalyzed α,β-unsaturated compounds.
Scheme 29: Conversion of p-quinone methides to benzylic silanes.
Scheme 30: Conversion of α,β-unsaturated ketimines to regio- and stereocontrolled allylic silanes.
Scheme 31: Conversion of α,β-unsaturated ketimines to enantioenriched allylic silanes.
Scheme 32: Regioselective conversion of dienedioates to allylic silanes.
Scheme 33: Conversion of alkenyl-substituted azaarenes to β-silylated adducts.
Scheme 34: Conversion of conjugated benzoxazoles to enantioenriched β-silylated adducts.
Scheme 35: Conversion of α,β-unsaturated carbonyl indoles to α-silylated N-alkylated indoles.
Scheme 36: Conversion of β-amidoacrylates to α-aminosilanes.
Scheme 37: Conversion of α,β-unsaturated ketones to enantioenriched β-silylated ketones, nitriles, and nitro d...
Scheme 38: Regio-divergent silacarboxylation of allenes.
Scheme 39: Silylation of diazocarbonyl compounds, (A) asymmetric and (B) racemic.
Scheme 40: Enantioselective hydrosilylation of alkenes.
Scheme 41: Conversion of 3-acylindoles to indolino-silanes.
Scheme 42: Proposed mechanism for the silylation of 3-acylindoles.
Scheme 43: Silyation of N-chlorosulfonamides.
Scheme 44: Conversion of acyl silanes to α-silyl alcohols.
Scheme 45: Conversion of N-tosylaziridines to β-silylated N-tosylamines.
Scheme 46: Conversion of N-tosylaziridines to silylated N-tosylamines.
Scheme 47: Conversion of 3,3-disubstituted cyclopropenes to silylated cyclopropanes.
Scheme 48: Conversion of conjugated enynes to 1,3-bis(silyl)propenes.
Scheme 49: Proposed sequence for the Cu-catalyzed borylation of substituted alkenes.
Scheme 50: Cu-catalyzed synthesis of nonracemic allylic boronates.
Scheme 51: Cu–NHC catalyzed synthesis of α-substituted allylboronates.
Scheme 52: Synthesis of α-chiral (γ-alkoxyallyl)boronates.
Scheme 53: Cu-mediated formation of nonracemic cis- or trans- 2-substituted cyclopropylboronates.
Scheme 54: Cu-catalyzed synthesis of γ,γ-gem-difluoroallylboronates.
Scheme 55: Cu-catalyzed hydrofunctionalization of internal alkenes and vinylarenes.
Scheme 56: Cu-catalyzed Markovnikov and anti-Markovnikov borylation of alkenes.
Scheme 57: Cu-catalyzed borylation/ortho-cyanation/Cope rearrangement.
Scheme 58: Borylfluoromethylation of alkenes.
Scheme 59: Cu-catalyzed synthesis of tertiary nonracemic alcohols.
Scheme 60: Synthesis of densely functionalized and synthetically versatile 1,2- or 4,3-borocyanated 1,3-butadi...
Scheme 61: Cu-catalyzed trifunctionalization of allenes.
Scheme 62: Cu-catalyzed selective arylborylation of arenes.
Scheme 63: Asymmetric borylative coupling between styrenes and imines.
Scheme 64: Regio-divergent aminoboration of unactivated terminal alkenes.
Scheme 65: Cu-catalyzed 1,4-borylation of α,β-unsaturated ketones.
Scheme 66: Cu-catalyzed protodeboronation of α,β-unsaturated ketones.
Scheme 67: Cu-catalyzed β-borylation of α,β-unsaturated imines.
Scheme 68: Cu-catalyzed synthesis of β-trifluoroborato carbonyl compounds.
Scheme 69: Asymmetric 1,4-borylation of α,β-unsaturated carbonyl compounds.
Scheme 70: Cu-catalyzed ACB and ACA reactions of α,β-unsaturated 2-acyl-N-methylimidazoles.
Scheme 71: Cu-catalyzed diborylation of aldehydes.
Scheme 72: Umpolung pathway for chiral, nonracemic tertiary alcohol synthesis (top) and proposed mechanism for...
Scheme 73: Cu-catalyzed synthesis of α-hydroxyboronates.
Scheme 74: Cu-catalyzed borylation of ketones.
Scheme 75: Cu-catalyzed borylation of unactivated alkyl halides.
Scheme 76: Cu-catalyzed borylation of allylic difluorides.
Scheme 77: Cu-catalyzed borylation of cyclic and acyclic alkyl halides.
Scheme 78: Cu-catalyzed borylation of unactivated alkyl chlorides and bromides.
Scheme 79: Cu-catalyzed decarboxylative borylation of carboxylic acids.
Scheme 80: Cu-catalyzed borylation of benzylic, allylic, and propargylic alcohols.
Beilstein J. Org. Chem. 2020, 16, 628–637, doi:10.3762/bjoc.16.59
Graphical Abstract
Figure 1: Chemical structures of the target diazine-based surrogates for the central core of panobinostat.
Figure 2: Docking pose for panobinostat and panobinostat derivatives in the HDAC8 receptor. (a) Overlay of al...
Figure 3: General building blocks for the visualized targets.
Scheme 1: Reaction conditions: a) MeOH, H2SO4 (5 drops), MS 4 Å (2 pieces), 68 °C, 8 h, 81%; b) DIBAL-H (1.2 ...
Scheme 2: Reaction conditions: a) boronic acid 15 (1.3 equiv), PdCl2(PPh3)2 (0.1 equiv), dioxane/H2O (3:1), Na...
Scheme 3: Reaction conditions: a) 5-bromo-2-chloropyrimidine (1 equiv), ethyl formate (1.5 equiv), THF (20 mL...
Scheme 4: Reaction conditions: a) boronic acid 15 (1.3 equiv), PdCl2(PPh3)2 (0.1 equiv), dioxane/H2O (8:2, Na2...
Beilstein J. Org. Chem. 2020, 16, 524–529, doi:10.3762/bjoc.16.48
Graphical Abstract
Figure 1: Examples of functional molecules based on π-extended phospholes.
Scheme 1: Syntheses of PAH-fused phospholes featuring a 7-hydroxybenzo[b]phosphole as a key intermediate.
Scheme 2: Synthesis of phosphole-fused ortho-teraryl compounds 7.
Scheme 3: Oxidative cyclization of phosphole-fused ortho-teraryl compounds 7 into triphenylene-fused phosphol...
Figure 2: ORTEP drawings of compound 8a (thermal ellipsoids set at 50% probability). a) top view; b) side vie...
Figure 3: UV–vis absorption (solid lines) and fluorescence (dashed lines) spectra of compounds 8a–c.
Beilstein J. Org. Chem. 2020, 16, 482–491, doi:10.3762/bjoc.16.43
Graphical Abstract
Scheme 1: Formation of sulfonyltriazoles and sulfonamidines.
Figure 1: Catalytic systems used in this study.
Scheme 2: Synthetic access to complexes 4–6 [30].
Scheme 3: Variation of sulfonylazides. Reaction conditions: phenylacetylene (0.5 mmol), sulfonyl azide (0.6 m...
Scheme 4: Variation of alkynes. Reaction conditions: alkyne (0.5 mmol), tosyl azide (0.6 mmol), diisopropylam...
Scheme 5: Variation of the amine substrate. Reaction conditions: phenylacetylene (0.5 mmol), tosyl azide (0.6...
Scheme 6: Reactivity of “non-sulfonyl” azide [33]. Reaction conditions: phenylacetylene (0.5 mmol), benzyl azide ...
Scheme 7: Reactivity of diphenylphosphoryl azide. Reaction conditions: phenylacetylene (0.5 mmol), diphenylph...
Scheme 8: Proposed mechanism for the formation of sulfonamidine.
Scheme 9: Stoichiometric reaction between 6 and 8.
Scheme 10: Synthesis of copper-acetylide intermediate A via [Cu(Cl)(Triaz)].
Scheme 11: Catalytic reaction involving copper-acetylide complex A.
Beilstein J. Org. Chem. 2020, 16, 305–316, doi:10.3762/bjoc.16.30
Graphical Abstract
Scheme 1: Process for the formation of C(sp3)–SeCF3 bonds with [(bpy)CuSeCF3]2 developed by the group of Weng....
Scheme 2: Trifluoromethylselenolation of vinyl and (hetero)aryl halides with [(bpy)CuSeCF3]2 by the group of ...
Scheme 3: Trifluoromethylselenolation of terminal alkynes using [(bpy)CuSeCF3]2 by the group of You and Weng.
Scheme 4: Trifluoromethylselenolation of carbonyl compounds with [(bpy)CuSeCF3]2 by the group of Weng.
Scheme 5: Trifluoromethylselenolation of α,β-unsaturated ketones with [(bpy)CuSeCF3]2 by the group of Weng.
Scheme 6: Trifluoromethylselenolation of acid chlorides with [(bpy)CuSeCF3]2 by the group of Weng.
Scheme 7: Synthesis of 2-trifluoromethylselenylated benzofused heterocycles with [(bpy)CuSeCF3]2 by the group...
Scheme 8: Difunctionalization of terminal alkenes and alkynes with [(bpy)CuSeCF3]2 by the group of Liang.
Scheme 9: Synthesis of Me4NSeCF3.
Scheme 10: Oxidative trifluoromethylselenolation of terminal alkynes and boronic acid derivatives with Me4NSeCF...
Scheme 11: Trifluoromethylselenolation of diazoacetates and diazonium salts with Me4NSeCF3 by the group of Goo...
Scheme 12: Trifluoromethylselenolation with ClSeCF3 by the group of Tlili and Billard.
Scheme 13: Trifluoromethylselenolation with TsSeCF3 by the group of Tlili and Billard.
Scheme 14: Copper-catalyzed synthesis of a selenylated analog 30 of Pretomanid developed by the group of Tlili...
Scheme 15: One-pot procedures for C–SeCF3 bond formations developed by Hor and Weng, Deng and Xiao, and Ruepin...
Beilstein J. Org. Chem. 2020, 16, 248–280, doi:10.3762/bjoc.16.26
Graphical Abstract
Figure 1: List of photoredox catalysts used for C–H bond functionalizations.
Figure 2: List of metal-based photoredox catalysts used in this review article.
Figure 3: Jablonski diagram.
Figure 4: Photoredox catalysis via reductive or oxidative pathways. D = donor, A = acceptor, S = substrate, P...
Figure 5: Schematic representation of the combination of photoredox catalysis and transition metal catalysis.
Scheme 1: Weinreb amide C–H olefination.
Figure 6: Mechanism for the formation of 21 from 19 using photoredox catalyst 11.
Scheme 2: C–H olefination of phenolic ethers.
Scheme 3: Decarboxylative acylation of acetanilides.
Figure 7: Mechanism for the formation of 30 from acetanilide derivatives.
Scheme 4: Synthesis of fluorenone derivatives by intramolecular deoxygenative acylation of biaryl carboxylic ...
Figure 8: Mechanism for the photoredox-catalyzed synthesis of fluorenone derivatives.
Scheme 5: Synthesis of benzothiazoles via aerobic C–H thiolation.
Figure 9: Plausible mechanism for the construction of benzothiazoles from benzothioamides.
Scheme 6: Synthesis of benzothiazoles via oxidant-free C–H thiolation.
Figure 10: Mechanism involved in the synthesis of benzothiazoles via oxidant-free C–H thiolation.
Scheme 7: Synthesis of indoles via C–H cyclization of anilides with alkynes.
Scheme 8: Preparation of 3-trifluoromethylcoumarins via C–H cyclization of arylpropiolate esters.
Figure 11: Mechanistic pathway for the synthesis of coumarin derivatives via C–H cyclization.
Scheme 9: Monobenzoyloxylation without chelation assistance.
Figure 12: Plausible mechanism for the formation of 71 from 70.
Scheme 10: Aryl-substituted arenes prepared by inorganic photoredox catalysis using 12a.
Figure 13: Proposed mechanism for C–H arylations in the presence of 12a and a Pd catalyst.
Scheme 11: Arylation of purines via dual photoredox catalysis.
Scheme 12: Arylation of substituted arenes with an organic photoredox catalyst.
Scheme 13: C–H trifluoromethylation.
Figure 14: Proposed mechanism for the trifluoromethylation of 88.
Scheme 14: Synthesis of benzo-3,4-coumarin derivatives.
Figure 15: Plausible mechanism for the synthesis of substituted coumarins.
Scheme 15: Oxidant-free oxidative phosphonylation.
Figure 16: Mechanism proposed for the phosphonylation reaction of 100.
Scheme 16: Nitration of anilines.
Figure 17: Plausible mechanism for the nitration of aniline derivatives via photoredox catalysis.
Scheme 17: Synthesis of carbazoles via intramolecular amination.
Figure 18: Proposed mechanism for the formation of carbazoles from biaryl derivatives.
Scheme 18: Synthesis of substituted phenols using QuCN.
Figure 19: Mechanism for the synthesis of phenol derivatives with photoredox catalyst 8.
Scheme 19: Synthesis of substituted phenols with DDQ (5).
Figure 20: Possible mechanism for the generation of phenols with the aid of photoredox catalyst 5.
Scheme 20: Aerobic bromination of arenes using an acridinium-based photocatalyst.
Scheme 21: Aerobic bromination of arenes with anthraquinone.
Figure 21: Proposed mechanism for the synthesis of monobrominated compounds.
Scheme 22: Chlorination of benzene derivatives with Mes-Acr-MeClO4 (2).
Figure 22: Mechanism for the synthesis of 131 from 132.
Scheme 23: Chlorination of arenes with 4CzIPN (5a).
Figure 23: Plausible mechanism for the oxidative photocatalytic monochlorination using 5a.
Scheme 24: Monofluorination using QuCN-ClO4 (8).
Scheme 25: Fluorination with fluorine-18.
Scheme 26: Aerobic amination with acridinium catalyst 3a.
Figure 24: Plausible mechanism for the aerobic amination using acridinium catalyst 3a.
Scheme 27: Aerobic aminations with semiconductor photoredox catalyst 18.
Scheme 28: Perfluoroalkylation of arenes.
Scheme 29: Synthesis of benzonitriles in the presence of 3a.
Figure 25: Plausible mechanism for the synthesis of substituted benzonitrile derivatives in the presence of 3a....
Beilstein J. Org. Chem. 2020, 16, 185–189, doi:10.3762/bjoc.16.21
Graphical Abstract
Scheme 1: Our strategy.
Scheme 2: Allylic cross-coupling using aldehydes as α-alkoxyalkyl anions.
Scheme 3: Substrate scope and reaction conditions. a) reactions were carried out with 1 (0.4 mmol), 2 (0.2 mm...
Scheme 4: Stoichiometric reaction.
Scheme 5: Possible pathway.
Beilstein J. Org. Chem. 2019, 15, 1996–2002, doi:10.3762/bjoc.15.195
Graphical Abstract
Figure 1: Inherent chirality generated by meta-substitution – the two structures are non-superposable mirror ...
Figure 2: General approach by Albrecht for MIC directed cyclometalation via C–H activation; M = Ru(II), Ir(II...
Figure 3: Concept of cyclometalated calix[4]arene target.
Scheme 1: Synthesis of model mesoionic carbene 5.
Scheme 2: Attempted Ullmann-coupling to give monoazide 7.
Scheme 3: Synthesis of monoazidocalix[4]arene 7 under optimized conditions.
Scheme 4: Synthesis of the putative calix[4]arene mesoionic carbene ruthenium complex 13.
Figure 4: High-resolution mass spectrum (ESI+) of putative ruthenacycle calix[4]arene 13.
Beilstein J. Org. Chem. 2019, 15, 1984–1995, doi:10.3762/bjoc.15.194
Graphical Abstract
Figure 1: Structures of triptolide (1), triptonide (2), tripdiolide (3), 16-hydroxytriptolide (4), triptrioli...
Figure 2: Syntheses of triptolide.
Scheme 1: Berchtold’s synthesis of triptolide.
Scheme 2: Li’s formal synthesis of triptolide.
Scheme 3: van Tamelen’s asymmetric synthesis of triptonide and triptolide.
Scheme 4: Van Tamelen’s (method II) formal synthesis of triptolide.
Scheme 5: Sherburn’s formal synthesis of triptolide.
Scheme 6: van Tamelen’s biogenetic type total synthesis of triptolide.
Scheme 7: Yang’s total synthesis of triptolide.
Scheme 8: Key intermediates or transformations of routes J–N.
Beilstein J. Org. Chem. 2019, 15, 1840–1847, doi:10.3762/bjoc.15.179
Graphical Abstract
Scheme 1: Accesses to tert-butyl 3,5-O-isopropylidene-3,5-dihydroxyhexanoates. (a) Previous methods using Cla...
Scheme 2: Attempted oxidations of 4.
Scheme 3: Preparations of 16 and related syn-1,3-diol compounds.
Scheme 4: Attempted oxidations of 6'.
Scheme 5: Attempted selective protections of internal 1,3-hydroxy groups: (a) acetonizations of 1,3-diols; (b...
Beilstein J. Org. Chem. 2019, 15, 1722–1757, doi:10.3762/bjoc.15.168
Graphical Abstract
Figure 1: Examples of three-carbon chirons.
Figure 2: Structures of derivatives of N-(1-phenylethyl)aziridine-2-carboxylic acid 5–8.
Figure 3: Synthetic equivalency of aziridine aldehydes 6.
Scheme 1: Synthesis of N-(1-phenylethyl)aziridine-2-carboxylates 5. Reagents and conditions: a) TEA, toluene,...
Scheme 2: Absolute configuration at C2 in (2S,1'S)-5a. Reagents and conditions: a) 20% HClO4, 80 °C, 30 h the...
Scheme 3: Major synthetic strategies for a 2-ketoaziridine scaffold [R* = (R)- or (S)-1-phenylethyl; R′ = Alk...
Scheme 4: Synthesis of cyanide (2S,1'S)-13. Reagents and conditions: a) NH3, EtOH/H2O, rt, 72 h; b) Ph3P, CCl4...
Scheme 5: Synthesis of key intermediates (R)-16 and (R)-17 for (R,R)-formoterol (14) and (R)-tamsulosin (15)....
Scheme 6: Synthesis of mitotic kinesin inhibitors (2R/S,1'R)-23. Reagents and conditions: a) H2, Pd(OH)2, EtO...
Scheme 7: Synthesis of (R)-mexiletine ((R)-24). Reagents and conditions: a) TsCl, TEA, DMAP, CH2Cl2, rt, 1 h;...
Scheme 8: Synthesis of (−)-cathinone ((S)-27). Reagents and conditions: a) PhMgBr, ether, 0 °C; b) H2, 10% Pd...
Scheme 9: Synthesis of N-Boc-norpseudoephedrine ((1S,2S)-(+)-29) and N-Boc-norephedrine ((1R,2S)-29). Reagent...
Scheme 10: Synthesis of (−)-ephedrine ((1R,2S)-31). Reagents and conditions: a) TfOMe, MeCN then NaBH3CN, rt; ...
Scheme 11: Synthesis of xestoaminol C ((2S,3R)-35), 3-epi-xestoaminol C ((2S,3S)-35) and N-Boc-spisulosine ((2S...
Scheme 12: Synthesis of ʟ-tryptophanol ((S)-41). Reagents and conditions: a) CDI, MeCN, rt, 1 h then TMSI, MeC...
Scheme 13: Synthesis of ʟ-homophenylalaninol ((S)-42). Reagents and conditions: a) NaH, THF, 0 °C to −78 °C, 1...
Scheme 14: Synthesis of ᴅ-homo(4-octylphenyl)alaninol ((R)-47) and a sphingolipid analogue (R)-48. Reagents an...
Scheme 15: Synthesis of florfenicol ((1R,2S)-49). Reagents and conditions: a) (S)-1-phenylethylamine, TEA, MeO...
Scheme 16: Synthesis of natural tyroscherin ((2S,3R,6E,8R,10R)-55). Reagents and conditions: a) I(CH2)3OTIPS, t...
Scheme 17: Syntheses of (−)-hygrine (S)-61, (−)-hygroline (2S,2'S)-62 and (−)-pseudohygroline (2S,2'R)-62. Rea...
Scheme 18: Synthesis of pyrrolidine (3S,3'R)-68, a fragment of the fluoroquinolone antibiotic PF-00951966. Rea...
Scheme 19: Synthesis of sphingolipid analogues (R)-76. Reagents and conditions: a) BnBr, Mg, THF, reflux, 6 h;...
Scheme 20: Synthesis of ᴅ-threo-PDMP (1R,2R)-81. Reagents and conditions: a) TMSCl, NaI, MeCN, rt, 1 h 50 min,...
Scheme 21: Synthesis of the sphingolipid analogue SG-14 (2S,3S)-84. Reagents and conditions: a) LiAlH4, THF, 0...
Scheme 22: Synthesis of the sphingolipid analogue SG-12 (2S,3R)-88. Reagents and conditions: a) 1-(bromomethyl...
Scheme 23: Synthesis of sphingosine-1-phosphate analogues DS-SG-44 and DS-SG-45 (2S,3R)-89a and (2S,3R)-89a. R...
Scheme 24: Synthesis of N-Boc-safingol ((2S,3S)-95) and N-Boc-ᴅ-erythro-sphinganine ((2S,3R)-95). Reagents and...
Scheme 25: Synthesis of ceramide analogues (2S,3R)-96. Reagents and conditions: a) NaBH4, ZnCl2, MeOH, −78 °C,...
Scheme 26: Synthesis of orthogonally protected serinols, (S)-101 and (R)-102. Reagents and conditions: a) BnBr...
Scheme 27: Synthesis of N-acetyl-3-phenylserinol ((1R,2R)-105). Reagents and conditions: a) AcOH, CH2Cl2, refl...
Scheme 28: Synthesis of (S)-linezolid (S)-107. Reagents and conditions: a) LiAlH4, THF, 0 °C to reflux; b) Boc2...
Scheme 29: Synthesis of (2S,3S,4R)-2-aminooctadecane-1,3,4-triol (ᴅ-ribo-phytosphingosine) (2S,3S,4R)-110. Rea...
Scheme 30: Syntheses of ᴅ-phenylalanine (R)-116. Reagents and conditions: a) AcOH, CH2Cl2, reflux, 4 h; b) MsC...
Scheme 31: Synthesis of N-Boc-ᴅ-3,3-diphenylalanine ((R)-122). Reagents and conditions: a) PhMgBr, THF, −78 °C...
Scheme 32: Synthesis of ethyl N,N’-di-Boc-ʟ-2,3-diaminopropanoate ((S)-125). Reagents and conditions: a) NaN3,...
Scheme 33: Synthesis of the bicyclic amino acid (S)-(+)-127. Reagents and conditions: a) BF3·OEt2, THF, 60 °C,...
Scheme 34: Synthesis of lacosamide, (R)-2-acetamido-N-benzyl-3-methoxypropanamide (R)-130. Reagents and condit...
Scheme 35: Synthesis of N-Boc-norfuranomycin ((2S,2'R)-133). Reagents and conditions: a) H2C=CHCH2I, NaH, THF,...
Scheme 36: Synthesis of MeBmt (2S,3R,4R,6E)-139. Reagents and conditions: a) diisopropyl (S,S)-tartrate (E)-cr...
Scheme 37: Synthesis of (+)-polyoxamic acid (2S,3S,4S)-144. Reagents and conditions: a) AD-mix-α, MeSO2NH2, t-...
Scheme 38: Synthesis of the protected 3-hydroxy-ʟ-glutamic acid (2S,3R)-148. Reagents and conditions: a) LiHMD...
Scheme 39: Synthesis of (+)-isoserine (R)-152. Reagents and conditions: a) AcCl, MeCN, rt, 0.5 h then Na2CO3, ...
Scheme 40: Synthesis of (3R,4S)-N3-Boc-3,4-diaminopentanoic acid (3R,4S)-155. Reagents and conditions: a) Ph3P...
Scheme 41: Synthesis of methyl (2S,3S,4S)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoate (2S,3S,4S)-159. ...
Scheme 42: Syntheses of methyl (3S,4S) 4,5-di-N-Boc-amino-3-hydroxypentanoate ((3S,4S)-164), methyl (3S,4S)-4-N...
Scheme 43: Syntheses of (3R,5S)-5-(aminomethyl)-3-(4-methoxyphenyl)dihydrofuran-2(3H)-one ((3R,5S)-168). Reage...
Scheme 44: Syntheses of a series of imidazolin-2-one dipeptides 175–177 (for R' and R'' see text). Reagents an...
Scheme 45: Syntheses of (2S,3S)-N-Boc-3-hydroxy-2-hydroxymethylpyrrolidine ((2S,3S)-179). Reagents and conditi...
Scheme 46: Syntheses of enantiomers of 1,4-dideoxy-1,4-imino-ʟ- and -ᴅ-lyxitols (2S,3R,4S)-182 and (2R,3S,4R)-...
Scheme 47: Synthesis of 1,4-dideoxy-1,4-imino-ʟ-ribitol (2S,3S,4R)-182. Reagents and conditions: a) AcOH, CH2Cl...
Scheme 48: Syntheses of 1,4-dideoxy-1,4-imino-ᴅ-arabinitol (2R,3R,4R)-182 and 1,4-dideoxy-1,4-imino-ᴅ-xylitol ...
Scheme 49: Syntheses of natural 2,5-imino-2,5,6-trideoxy-ʟ-gulo-heptitol ((2S,3R,4R,5R)-184) and its C4 epimer...
Scheme 50: Syntheses of (−)-dihydropinidine ((2S,6R)-187a) (R = C3H7) and (2S,6R)-isosolenopsins (2S,6R)-187b ...
Scheme 51: Syntheses of (+)-deoxocassine ((2S,3S,6R)-190a, R = C12H25) and (+)-spectaline ((2S,3S,6R)-190b, R ...
Scheme 52: Synthesis of (−)-microgrewiapine A ((2S,3R,6S)-194a) and (+)-microcosamine A ((2S,3R,6S)-194b). Rea...
Scheme 53: Syntheses of ʟ-1-deoxynojirimycin ((2S,3S,4S,5R)-200), ʟ-1-deoxymannojirimycin ((2S,3S,4S,5S)-200) ...
Scheme 54: Syntheses of 1-deoxy-ᴅ-galacto-homonojirimycin (2R,3S,4R,5S)-211. Reagents and conditions: a) MeONH...
Scheme 55: Syntheses of 7a-epi-hyacinthacine A1 (1S,2R,3R,7aS)-220. Reagents and conditions: a) TfOTBDMS, 2,6-...
Scheme 56: Syntheses of 8-deoxyhyacinthacine A1 ((1S,2R,3R,7aR)-221). Reagents and conditions: a) H2, Pd/C, PT...
Scheme 57: Syntheses of (+)-lentiginosine ((1S,2S,8aS)-227). Reagents and conditions: a) (EtO)2P(O)CH2COOEt, L...
Scheme 58: Syntheses of 8-epi-swainsonine (1S,2R,8S,8aR)-231. Reagents and conditions: a) Ph3P=CHCOOMe, MeOH, ...
Scheme 59: Synthesis of a protected vinylpiperidine (2S,3R)-237, a key intermediate in the synthesis of (−)-sw...
Scheme 60: Synthesis of a modified carbapenem 245. Reagents and conditions: a) AcOEt, LiHMDS, THF, −78 °C, 1.5...
Beilstein J. Org. Chem. 2019, 15, 1612–1704, doi:10.3762/bjoc.15.165
Graphical Abstract
Figure 1: Various drugs having IP nucleus.
Figure 2: Participation percentage of various TMs for the syntheses of IPs.
Scheme 1: CuI–NaHSO4·SiO2-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 2: Experimental examination of reaction conditions.
Scheme 3: One-pot tandem reaction for the synthesis of 2-haloimidazopyridines.
Scheme 4: Mechanistic scheme for the synthesis of 2-haloimidazopyridine.
Scheme 5: Copper-MOF-catalyzed three-component reaction (3-CR) for imidazo[1,2-a]pyridines.
Scheme 6: Mechanism for copper-MOF-driven synthesis.
Scheme 7: Heterogeneous synthesis via titania-supported CuCl2.
Scheme 8: Mechanism involving oxidative C–H functionalization.
Scheme 9: Heterogeneous synthesis of IPs.
Scheme 10: One-pot regiospecific synthesis of imidazo[1,2-a]pyridines.
Scheme 11: Vinyl azide as an unprecedented substrate for imidazo[1,2-a]pyridines.
Scheme 12: Radical pathway.
Scheme 13: Cu(I)-catalyzed transannulation approach for imidazo[1,5-a]pyridines.
Scheme 14: Plausible radical pathway for the synthesis of imidazo[1,5-a]pyridines.
Scheme 15: A solvent-free domino reaction for imidazo[1,2-a]pyridines.
Scheme 16: Cu-NPs-mediated synthesis of imidazo[1,2-a]pyridines.
Scheme 17: CuI-catalyzed synthesis of isoxazolylimidazo[1,2-a]pyridines.
Scheme 18: Functionalization of 4-bromo derivative via Sonogashira coupling reaction.
Scheme 19: A plausible reaction pathway.
Scheme 20: Cu(I)-catalyzed intramolecular oxidative C–H amidation reaction.
Scheme 21: One-pot synthetic reaction for imidazo[1,2-a]pyridine.
Scheme 22: Plausible reaction mechanism.
Scheme 23: Cu(OAc)2-promoted synthesis of imidazo[1,2-a]pyridines.
Scheme 24: Mechanism for aminomethylation/cycloisomerization of propiolates with imines.
Scheme 25: Three-component synthesis of imidazo[1,2-a]pyridines.
Figure 3: Scope of pyridin-2(1H)-ones and acetophenones.
Scheme 26: CuO NPS-promoted A3 coupling reaction.
Scheme 27: Cu(II)-catalyzed C–N bond formation reaction.
Scheme 28: Mechanism involving Chan–Lam/Ullmann coupling.
Scheme 29: Synthesis of formyl-substituted imidazo[1,2-a]pyridines.
Scheme 30: A tandem sp3 C–H amination reaction.
Scheme 31: Probable mechanistic approach.
Scheme 32: Dual catalytic system for imidazo[1,2-a]pyridines.
Scheme 33: Tentative mechanism.
Scheme 34: CuO/CuAl2O4/ᴅ-glucose-promoted 3-CCR.
Scheme 35: A tandem CuOx/OMS-2-based synthetic strategy.
Figure 4: Biomimetic catalytic oxidation in the presence of electron-transfer mediators (ETMs).
Scheme 36: Control experiment.
Scheme 37: Copper-catalyzed C(sp3)–H aminatin reaction.
Scheme 38: Reaction of secondary amines.
Scheme 39: Probable mechanistic pathway.
Scheme 40: Coupling reaction of α-azidoketones.
Scheme 41: Probable pathway.
Scheme 42: Probable mechanism with free energy calculations.
Scheme 43: MCR for cyanated IP synthesis.
Scheme 44: Substrate scope for the reaction.
Scheme 45: Reaction mechanism.
Scheme 46: Probable mechanistic pathway for Cu/ZnAl2O4-catalyzed reaction.
Scheme 47: Copper-catalyzed double oxidative C–H amination reaction.
Scheme 48: Application towards different coupling reactions.
Scheme 49: Reaction mechanism.
Scheme 50: Condensation–cyclization approach for the synthesis of 1,3-diarylated imidazo[1,5-a]pyridines.
Scheme 51: Optimized reaction conditions.
Scheme 52: One-pot 2-CR.
Scheme 53: One-pot 3-CR without the isolation of chalcone.
Scheme 54: Copper–Pybox-catalyzed cyclization reaction.
Scheme 55: Mechanistic pathway catalyzed by Cu–Pybox complex.
Scheme 56: Cu(II)-promoted C(sp3)-H amination reaction.
Scheme 57: Wider substrate applicability for the reaction.
Scheme 58: Plausible reaction mechanism.
Scheme 59: CuI assisted C–N cross-coupling reaction.
Scheme 60: Probable reaction mechanism involving sp3 C–H amination.
Scheme 61: One-pot MCR-catalyzed by CoFe2O4/CNT-Cu.
Scheme 62: Mechanistic pathway.
Scheme 63: Synthetic scheme for 3-nitroimidazo[1,2-a]pyridines.
Scheme 64: Plausible mechanism for CuBr-catalyzed reaction.
Scheme 65: Regioselective synthesis of halo-substituted imidazo[1,2-a]pyridines.
Scheme 66: Synthesis of 2-phenylimidazo[1,2-a]pyridines.
Scheme 67: Synthesis of diarylated compounds.
Scheme 68: CuBr2-mediated one-pot two-component oxidative coupling reaction.
Scheme 69: Decarboxylative cyclization route to synthesize 1,3-diarylimidazo[1,5-a]pyridines.
Scheme 70: Mechanistic pathway.
Scheme 71: C–H functionalization reaction of enamines to produce diversified heterocycles.
Scheme 72: A plausible mechanism.
Scheme 73: CuI-promoted aerobic oxidative cyclization reaction of ketoxime acetates and pyridines.
Scheme 74: CuI-catalyzed pathway for the formation of imidazo[1,2-a]pyridine.
Scheme 75: Mechanistic pathway.
Scheme 76: Mechanistic rationale for the synthesis of products.
Scheme 77: Copper-catalyzed synthesis of vinyloxy-IP.
Scheme 78: Regioselective product formation with propiolates.
Scheme 79: Proposed mechanism for vinyloxy-IP formation.
Scheme 80: Regioselective synthesis of 3-hetero-substituted imidazo[1,2-a]pyridines with different reaction su...
Scheme 81: Mechanistic pathway.
Scheme 82: CuI-mediated synthesis of 3-formylimidazo[1,2-a]pyridines.
Scheme 83: Radical pathway for 3-formylated IP synthesis.
Scheme 84: Pd-catalyzed urea-cyclization reaction for IPs.
Scheme 85: Pd-catalyzed one-pot-tandem amination and intramolecular amidation reaction.
Figure 5: Scope of aniline nucleophiles.
Scheme 86: Pd–Cu-catalyzed Sonogashira coupling reaction.
Scheme 87: One-pot amide coupling reaction for the synthesis of imidazo[4,5-b]pyridines.
Scheme 88: Urea cyclization reaction for the synthesis of two series of pyridines.
Scheme 89: Amidation reaction for the synthesis of imidazo[4,5-b]pyridines.
Figure 6: Amide scope.
Scheme 90: Pd NPs-catalyzed 3-component reaction for the synthesis of 2,3-diarylated IPs.
Scheme 91: Plausible mechanistic pathway for Pd NPs-catalyzed MCR.
Scheme 92: Synthesis of chromenoannulated imidazo[1,2-a]pyridines.
Scheme 93: Mechanism for the synthesis of chromeno-annulated IPs.
Scheme 94: Zinc oxide NRs-catalyzed synthesis of imidazo[1,2-a]azines/diazines.
Scheme 95: Zinc oxide-catalyzed isocyanide based GBB reaction.
Scheme 96: Reaction pathway for ZnO-catalyzed GBB reaction.
Scheme 97: Mechanistic pathway.
Scheme 98: ZnO NRs-catalyzed MCR for the synthesis of imidazo[1,2-a]azines.
Scheme 99: Ugi type GBB three-component reaction.
Scheme 100: Magnetic NPs-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 101: Regioselective synthesis of 2-alkoxyimidazo[1,2-a]pyridines catalyzed by Fe-SBA-15.
Scheme 102: Plausible mechanistic pathway for the synthesis of 2-alkoxyimidazopyridine.
Scheme 103: Iron-catalyzed synthetic approach.
Scheme 104: Iron-catalyzed aminooxygenation reaction.
Scheme 105: Mechanistic pathway.
Scheme 106: Rh(III)-catalyzed double C–H activation of 2-substituted imidazoles and alkynes.
Scheme 107: Plausible reaction mechanism.
Scheme 108: Rh(III)-catalyzed non-aromatic C(sp2)–H bond activation–functionalization for the synthesis of imid...
Scheme 109: Reactivity and selectivity of different substrates.
Scheme 110: Rh-catalyzed direct C–H alkynylation by Li et al.
Scheme 111: Suggested radical mechanism.
Scheme 112: Scandium(III)triflate-catalyzed one-pot reaction and its mechanism for the synthesis of benzimidazo...
Scheme 113: RuCl3-assisted Ugi-type Groebke–Blackburn condensation reaction.
Scheme 114: C-3 aroylation via Ru-catalyzed two-component reaction.
Scheme 115: Regioselective synthetic mechanism.
Scheme 116: La(III)-catalyzed one-pot GBB reaction.
Scheme 117: Mechanistic approach for the synthesis of imidazo[1,2-a]pyridines.
Scheme 118: Synthesis of imidazo[1,2-a]pyridine using LaMnO3 NPs under neat conditions.
Scheme 119: Mechanistic approach.
Scheme 120: One-pot 3-CR for regioselective synthesis of 2-alkoxy-3-arylimidazo[1,2-a]pyridines.
Scheme 121: Formation of two possible products under optimization of the catalysts.
Scheme 122: Mechanistic strategy for NiFe2O4-catalyzed reaction.
Scheme 123: Two-component reaction for synthesizing imidazodipyridiniums.
Scheme 124: Mechanistic scheme for the synthesis of imidazodipyridiniums.
Scheme 125: CuI-catalyzed arylation of imidazo[1,2-a]pyridines.
Scheme 126: Mechanism for arylation reaction.
Scheme 127: Cupric acetate-catalyzed double carbonylation approach.
Scheme 128: Radical mechanism for double carbonylation of IP.
Scheme 129: C–S bond formation reaction catalyzed by cupric acetate.
Scheme 130: Cupric acetate-catalyzed C-3 formylation approach.
Scheme 131: Control experiments for signifying the role of DMSO and oxygen.
Scheme 132: Mechanism pathway.
Scheme 133: Copper bromide-catalyzed CDC reaction.
Scheme 134: Extension of the substrate scope.
Scheme 135: Plausible radical pathway.
Scheme 136: Transannulation reaction for the synthesis of imidazo[1,5-a]pyridines.
Scheme 137: Plausible reaction pathway for denitrogenative transannulation.
Scheme 138: Cupric acetate-catalyzed C-3 carbonylation reaction.
Scheme 139: Plausible mechanism for regioselective C-3 carbonylation.
Scheme 140: Alkynylation reaction at C-2 of 3H-imidazo[4,5-b]pyridines.
Scheme 141: Two-way mechanism for C-2 alkynylation of 3H-imidazo[4,5-b]pyridines.
Scheme 142: Palladium-catalyzed SCCR approach.
Scheme 143: Palladium-catalyzed Suzuki coupling reaction.
Scheme 144: Reaction mechanism.
Scheme 145: A phosphine free palladium-catalyzed synthesis of C-3 arylated imidazopyridines.
Scheme 146: Palladium-mediated Buchwald–Hartwig cross-coupling reaction.
Figure 7: Structure of the ligands optimized.
Scheme 147: Palladium acetate-catalyzed direct arylation of imidazo[1,2-a]pyridines.
Scheme 148: Palladium acetate-catalyzed mechanistic pathway.
Scheme 149: Palladium acetate-catalyzed regioselective arylation reported by Liu and Zhan.
Scheme 150: Mechanism for selective C-3 arylation of IP.
Scheme 151: Pd(II)-catalyzed alkenylation reaction with styrenes.
Scheme 152: Pd(II)-catalyzed alkenylation reaction with acrylates.
Scheme 153: A two way mechanism.
Scheme 154: Double C–H activation reaction catalyzed by Pd(OAc)2.
Scheme 155: Probable mechanism.
Scheme 156: Palladium-catalyzed decarboxylative coupling.
Scheme 157: Mechanistic cycle for decarboxylative arylation reaction.
Scheme 158: Ligand-free approach for arylation of imidazo[1,2-a]pyridine-3-carboxylic acids.
Scheme 159: Mechanism for ligandless arylation reaction.
Scheme 160: NHC-Pd(II) complex assisted arylation reaction.
Scheme 161: C-3 arylation of imidazo[1,2-a]pyridines with aryl bromides catalyzed by Pd(OAc)2.
Scheme 162: Pd(II)-catalyzed C-3 arylations with aryl tosylates and mesylates.
Scheme 163: CDC reaction for the synthesis of imidazo[1,2-a]pyridines.
Scheme 164: Plausible reaction mechanism for Pd(OAc)2-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 165: Pd-catalyzed C–H amination reaction.
Scheme 166: Mechanism for C–H amination reaction.
Scheme 167: One-pot synthesis for 3,6-di- or 2,3,6-tri(hetero)arylimidazo[1,2-a]pyridines.
Scheme 168: C–H/C–H cross-coupling reaction of IPs and azoles catalyzed by Pd(II).
Scheme 169: Mechanistic cycle.
Scheme 170: Rh-catalyzed C–H arylation reaction.
Scheme 171: Mechanistic pathway for C–H arylation of imidazo[1,2-a]pyridine.
Scheme 172: Rh(III)-catalyzed double C–H activation of 2-phenylimidazo[1,2-a]pyridines and alkynes.
Scheme 173: Rh(III)-catalyzed mechanistic pathway.
Scheme 174: Rh(III)-mediated oxidative coupling reaction.
Scheme 175: Reactions showing functionalization of the product obtained by the group of Kotla.
Scheme 176: Mechanism for Rh(III)-catalyzed oxidative coupling reaction.
Scheme 177: Rh(III)-catalyzed C–H activation reaction.
Scheme 178: Mechanistic cycle.
Scheme 179: Annulation reactions of 2-arylimidazo[1,2-a]pyridines and alkynes.
Scheme 180: Two-way reaction mechanism for annulations reaction.
Scheme 181: [RuCl2(p-cymene)]2-catalyzed C–C bond formation reaction.
Scheme 182: Reported reaction mechanism.
Scheme 183: Fe(III) catalyzed C-3 formylation approach.
Scheme 184: SET mechanism-catalyzed by Fe(III).
Scheme 185: Ni(dpp)Cl2-catalyzed KTC coupling.
Scheme 186: Pd-catalyzed SM coupling.
Scheme 187: Vanadium-catalyzed coupling of IP and NMO.
Scheme 188: Mechanistic cycle.
Scheme 189: Selective C3/C5–H bond functionalizations by mono and bimetallic systems.
Scheme 190: rGO-Ni@Pd-catalyzed C–H bond arylation of imidazo[1,2-a]pyridine.
Scheme 191: Mechanistic pathway for heterogeneously catalyzed arylation reaction.
Scheme 192: Zinc triflate-catalyzed coupling reaction of substituted propargyl alcohols.
Beilstein J. Org. Chem. 2019, 15, 1569–1574, doi:10.3762/bjoc.15.160
Graphical Abstract
Figure 1: Proposed mechanism of the asymmetric aza-Piancatelli reaction.
Scheme 1: Asymmetric aza-Piancatelli rearrangement with a range of substituted anilines. *To simplify the pur...
Scheme 2: Asymmetric aza-Piancatelli rearrangement with a range of substituted furylcarbinols. *To simplify t...
Beilstein J. Org. Chem. 2019, 15, 1468–1474, doi:10.3762/bjoc.15.147
Graphical Abstract
Figure 1: Structure of abyssomicins C, B, D, atrop-abyssomicin C, atrop-O-benzyl-abyssomicin C and atrop-O-be...
Figure 2: A) Docking poses for atrop-O-benzyl-desmethyl-abyssomicin C (orange) and compound 2 (green) showing...
Scheme 1: Retrosynthetic analysis of the truncated derivatives 1 and 2 of abyssomicin C.
Scheme 2: Synthesis of the building block 3. a) TBDMSCl (0.5 equiv), NaH (1.0 equiv), THF, 0 °C to rt, 16 h, ...
Scheme 3: Synthesis of the building blocks 4 and 5. a) TFA (1.1 equiv), CH2Cl2, rt, 24 h, 84% (14: R = Me) an...
Scheme 4: Reaction of the building block 3 with 4 or 5 for the synthesis of compounds 1 and 2. a) 4 or 5 with...
Beilstein J. Org. Chem. 2019, 15, 1289–1297, doi:10.3762/bjoc.15.127
Graphical Abstract
Figure 1: Рharmacologically active sulfones.
Figure 2: Structures of the ligands L1–L8.
Figure 3: Evolution of the conversion of 5 and diastereomeric composition of the products of reaction of 5a w...
Figure 4: Time profile of epimerization and retro-Michael reaction of (2R,3S)-8a in chloroform-d solution.
Figure 5: ORTEP diagram of (2R,3S)-8d.
Scheme 1: The proposed mechanism of asymmetric addition of β-ketosulfones to nitroalkenes.
Scheme 2: Transition state models for asymmetric addition of β-ketosulfones to nitroalkenes.
Beilstein J. Org. Chem. 2019, 15, 955–962, doi:10.3762/bjoc.15.92
Graphical Abstract
Scheme 1: Chiral biphenyl diol organocatalysts 1–6.
Scheme 2: Synthesis of 3.
Figure 1: (a) Single crystal X-ray structure of 3: showing intra- and intermolecular hydrogen bonds (green da...
Scheme 3: Synthesis of 4.
Scheme 4: Synthesis of 6.
Figure 2: X-ray crystal structure of (P)-(S,S)-6 at two different orientations to show (a) P atropselectiviti...
Beilstein J. Org. Chem. 2019, 15, 721–726, doi:10.3762/bjoc.15.67
Graphical Abstract
Scheme 1: Synthesis of 4,5-dihydroisobenzofuran-5-ol (3).
Scheme 2: Protection strategy of 4,5-dihydroisobenzofuran-5-ol (3).
Scheme 3: Oxidation of 5-substituted-4,5-dihydroisobenzofuran-5-ol in presence of SeO2 or DDQ.
Scheme 4: Synthesis of 4-hydroxy-ortho-phthalaldehyde (6) through MAOS demethylation of 4-methoxy-ortho-phtha...
Beilstein J. Org. Chem. 2019, 15, 710–720, doi:10.3762/bjoc.15.66
Graphical Abstract
Figure 1: Schematic representation of β-CD with glucopyranose atom numbering and with alphabetic labeling of ...
Scheme 1: Syntheses of 6A,6X-diazido-β-CDs as reference compounds using the “capping” literature method [11,12].
Scheme 2: Syntheses of homo-difunctionalized β-CDs using different reaction conditions.
Figure 2: HPLC chromatograms of the authentic 6A,6X-diazido-β-CDs with known regiochemistry (references 1–3, Scheme 1...
Figure 3: NMR spectral regions of the three ditosyl regioisomers in D2O (500 MHz). The signals of the tosylat...
Scheme 3: Syntheses of 6A-monoazido-6X-monotosyl-β-CDs using starting materials obtained from different react...
Figure 4: Reversed-phase HPLC chromatograms of 6A-monoazido-6X-monotosyl-β-CDs prepared through reactions 4–8....
Figure 5: HPLC separation of regioisomers and pseudoenantiomers of 6A-monoazido-6X-monotosyl-β-CD prepared in...
Figure 6: Reversed-phase HPLC chromatograms of 6A,6X-diazido-β-CDs prepared in reactions 9–13.
Beilstein J. Org. Chem. 2019, 15, 445–468, doi:10.3762/bjoc.15.39
Graphical Abstract
Scheme 1: Most common metathesis reactions. Ring-opening metathesis polymerization (ROMP), acyclic diene meta...
Scheme 2: Catalytic cycle for metathesis proposed by Chauvin.
Figure 1: Some of the most representative catalysts for aqueous metathesis. a) Well-defined ruthenium catalys...
Scheme 3: First aqueous ROMP reactions catalyzed by ruthenium(III) salts.
Scheme 4: Degradation pathway of first generation Grubbs catalyst (G-I) in methanol.
Scheme 5: Synthesis of Blechert-type catalysts 19 and 20.
Figure 2: Chemical structure and components of amphiphilic molecule PTS and derivatives.
Scheme 6: RCM of selected substrates in the presence of the surfactant PTS. Conditionsa: The reaction was car...
Scheme 7: RCM reactions of substrates 31 and 33 with the encapsulated G-II catalyst.
Scheme 8: Living ROMP of norbornene derivatives 35 and 36 with phosphine-based catalysts bearing quaternary a...
Scheme 9: Synthesis of water-soluble catalysts 3 and 4 bearing quaternary ammonium tags.
Scheme 10: In situ formation of catalyst 5 bearing a quaternary ammonium group.
Scheme 11: Catalyst recycling of an ammonium-bearing catalyst.
Scheme 12: Removal of the water-soluble catalyst 12 through host–guest interaction with silica-gel-supported β...
Scheme 13: Selection of artificial metathases reported by Ward and co-workers (ArM 1 based on biotin–(strept)a...
Figure 3: In vivo metathesis with an artificial metalloenzyme based on the biotin–streptavidin technology.
Scheme 14: Artificial metathase based on covalent anchoring approach. α-Chymotrypsin interacts with catalyst 66...
Scheme 15: Assembling an artificial metathase (ArM 4) based on the small heat shock protein from M. Jannaschii...
Scheme 16: Artificial metathases based on cavity-size engineered β-barrel protein nitrobindin (NB4exp). The HG...
Scheme 17: Artificial metathase based on cutinase (ArM 8) and resulting metathesis activities.
Scheme 18: Site-specific modification of proteins via aqueous cross-metathesis. The protein structure is based...
Scheme 19: a) Allyl homocysteine (Ahc)-modified proteins as CM substrates. b) Incorporation of Ahc in the Fc p...
Scheme 20: On-DNA cross-metathesis reaction of allyl sulfide 99.
Scheme 21: Preparation of BODIPY-containing profluorescent probes 102 and 104.
Scheme 22: Metathesis-based ethylene detection in live cells.
Scheme 23: First example of stapled peptides via olefin metathesis.
Beilstein J. Org. Chem. 2018, 14, 3078–3087, doi:10.3762/bjoc.14.287
Graphical Abstract
Figure 1: Biologically relevant imidazo[1,2-a]pyridines and chromenes.
Scheme 1: Domino formation of imidazopyridines and current work.
Scheme 2: Scope of the reaction between N-(cyanomethyl)pyridinium chloride, o-hydroxybenzaldehydes, and nitro...
Scheme 3: Scope of the reaction of o-hydroxybenzaldehydes with N-(cyanomethyl)pyridinium chloride and indoles...
Scheme 4: Scope of the nucleophiles in the reaction of o-hydroxyarylaldehydes with N-(cyanomethyl)pyridinium ...
Scheme 5: N-(Cyanomethyl)thieno[2,3-c]pyridinium chloride (15) and 6-(cyanomethyl)-1-methyl-1H-pyrrolo[2,3-c]...
Figure 2: General view of the molecule 7b in the crystal state (CCDC 1849215). Anisotropic displacement param...
Scheme 6: The presumed mechanism for the formation of target chromenoimidazopyridines (reaction 1) and additi...
Beilstein J. Org. Chem. 2018, 14, 2949–2955, doi:10.3762/bjoc.14.274
Graphical Abstract
Figure 1: N,N-Dimethyl-L-vancosamine as substructure of kidamycin and pluramycin.
Figure 2: Glycals as relevant scaffolds for constructing aryl C-glycosidic linkage.
Figure 3: Strategy including a ring-closing metathesis of vinyl ethers as key step for the preparation of sev...
Scheme 1: Evans aldol reaction for the preparation of diastereomeric compounds 13a and 13b.
Scheme 2: Alternative preparation of 13b based on a diastereoselective allylboration.
Scheme 3: O-Vinylation-ring-closing metathesis sequence for access to 3-amino glycals.
Scheme 4: Synthesis of key intermediate 23 for the C-3 unbranched amino glycals preparation.
Scheme 5: Access to diastereoisomeric compounds 3 and 4 from 23.
Beilstein J. Org. Chem. 2018, 14, 2822–2828, doi:10.3762/bjoc.14.260
Graphical Abstract
Figure 1: Structures of hamamelitannin (1), lead compound 2 and target compounds 3.
Scheme 1: Proposed strategy for the synthesis of the target analogues.
Scheme 2: Synthesis of fragment 9. Reagents and conditions: a) phthalimide, Pd2(allyl)2Cl2, ligand 15, Na2CO3...
Scheme 3: Synthesis of fragment 10. Reagents and conditions: a) TBSCl, NaH, THF, rt; b) phthalimide, PPh3, DE...
Scheme 4: Coupling of 9 and 10 and attempted ring-closing metathesis. Reagents and conditions: a) PPh3, DEAD,...
Scheme 5: Synthesis of alternative eastern fragment 23. Reagents and conditions: a) TBSCl, imidazole, CH2Cl2,...
Scheme 6: Synthesis of 4. Reagents and conditions: a) PPh3, DEAD, THF, 0 °C to rt; b) Grubbs–Hoveyda II (5 mo...
Scheme 7: Late stage functionalization of the pyrrolidine nitrogen. Reagents and conditions: A) (masked) alde...
Figure 2: Molecular X-ray structure of 3a, showing thermal displacement ellipsoids at the 50% probability lev...